Colgate-Palmolive (CL)
NYSEConsumer StaplesHousehold & Personal ProductsSnapshot 2026-07-08
$93.03-2.10%
Close 2026-07-08 · 1-day change
Reading CL? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track CL free→NYSEConsumer StaplesHousehold & Personal ProductsSnapshot 2026-07-08
Reading CL? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track CL free→QuarterlyIQ Insights · CL
Price, fair value, and the multiples that frame it on the same time axis. Scroll over the price chart to zoom.
Daily closes. Earnings/event dots inline.
A consensus fair price across 13 valuation methods, at three horizons. Current price $93.03. As of 2026-07-09. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 10% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $93 the market pays 25× p/e — above the 19× p/e peer median but in line with its own 25× history. That premium reflects a durable franchise our peer-anchored $87 fair value understates; treat the 'expensive vs peers' read with medium confidence. Analysts target $79–$102. Not investment advice.
$79.00 – $102.00 (median $96.00) · 9 analysts · as of 2026-07-08
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
No fragility gates fired. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
At today's price the business can't be justified by any reasonable horizon of the forecast growth; the price already runs past what the model can underwrite. These describe the expectations embedded in the price, not a forecast of the move. Reverse-DCF base: $3.31/sh owner earnings.
Looks more expensive than peers.
Around its own typical valuation.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
Score 100 = cheapest in the cohort, 0 = richest. Bars are filled left-to-right based on the peer-relative score (or PEG/self-history where shown).
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Each method's implied share price per horizon. Provisional rows use a projected (historical-CAGR) growth input rather than analyst or management guidance.
| Method | Horizon | Est. price | Multiple | Per-share input | EPS source | Confidence |
|---|---|---|---|---|---|---|
| analyst target | 12M | $96.00 | — | — | Analyst | high |
| dcf fcfe | 12M | $141.56 | — | — | Hist. CAGR | high |
| dcf fcff | 12M | $143.81 | — | — | Hist. CAGR | high |
| ddm gordon | 12M | $30.81 | — | — | TTM | high |
| Mgmt guidance | 12M | $16.35 | 19.0 | 0.86 | Mgmt | high |
| Peer EV/EBITDA | 12M | $90.42 | 16.6 | 5.95 | TTM | high |
| Peer P/FCF | 12M | $93.36 | 20.0 | 4.68 | TTM | high |
| Peer P/E | 12M | $71.31 | 19.0 | 3.75 | TTM | high |
| Peer P/S | 12M | $43.69 | 1.7 | 25.83 | TTM | high |
| PEG | 12M | $65.30 | 17.4 | 3.75 | TTM | high |
| residual income | 12M | $14.50 | — | — | TTM | high |
| Own P/E history | 12M | $94.37 | 25.2 | 3.75 | TTM | high |
| triangulated | 12M | $74.82 | 19.0 | 3.93 | Triangulated | high |
| Mgmt guidance | 3Y | $19.05 | 19.0 | 1.00 | Mgmt(prov.) | medium |
| Peer P/FCF | 3Y | $141.99 | 20.0 | 7.12 | Hist. CAGR(prov.) | medium |
| Peer P/E | 3Y | $84.31 | 19.0 | 4.43 | Analyst | medium |
| Peer P/S | 3Y | $51.05 | 1.7 | 30.18 | guidance | medium |
| PEG | 3Y | $77.20 | 17.4 | 4.43 | Analyst | medium |
| Own P/E history | 3Y | $111.57 | 25.2 | 4.43 | Analyst | medium |
| Mgmt guidance | 5Y | $21.08 | 19.0 | 1.11 | Mgmt(prov.) | high |
| Peer P/FCF | 5Y | $187.79 | 20.0 | 9.41 | Hist. CAGR(prov.) | high |
| Peer P/E | 5Y | $94.73 | 19.0 | 4.98 | Analyst | high |
| Peer P/S | 5Y | $57.36 | 1.7 | 33.91 | guidance | high |
| PEG | 5Y | $86.75 | 17.4 | 4.98 | Analyst | high |
| Own P/E history | 5Y | $125.37 | 25.2 | 4.98 | Analyst | high |
A “consensus-then vs. actual-now” overlay is on the way — what our valuation estimate said on a past date versus where the price actually landed.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.